Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

1.

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens.

Muir AJ, Gong L, Johnson SG, Lee MT, Williams MS, Klein TE, Caudle KE, Nelson DR; Clinical Pharmacogenetics Implementation Consortium (CPIC).

Clin Pharmacol Ther. 2014 Feb;95(2):141-6. doi: 10.1038/clpt.2013.203. Epub 2013 Oct 4.

PMID:
24096968
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.

Itokawa N, Atsukawa M, Tsubota A, Kondo C, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Narahara Y, Nakatsuka K, Kanazawa H, Iwakiri K, Sakamoto C.

J Gastroenterol Hepatol. 2013 Mar;28(3):443-9. doi: 10.1111/jgh.12039.

PMID:
23173698
[PubMed - indexed for MEDLINE]
3.

Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.

Jabłonowska E, Piekarska A, Koślińska-Berkan E, Omulecka A, Szymańska B, Wójcik K.

Acta Biochim Pol. 2012;59(3):333-7. Epub 2012 Aug 27.

PMID:
22924160
[PubMed - indexed for MEDLINE]
Free Article
4.

Pegylated interferon-α monotherapy leads to low response rates in HIV-infected patients with acute hepatitis C.

Arends JE, van Assen S, Stek CJ, Wensing AM, Fransen JH, Schellens IM, Spijkers SN, Mudrikova T, van Baarle D, Sprenger HG, Hoepelman AI.

Antivir Ther. 2011;16(7):979-88. doi: 10.3851/IMP1843.

PMID:
22024513
[PubMed - indexed for MEDLINE]
5.

Estimation of two real-time RT-PCR assays for quantitation of hepatitis C virus RNA during PEG-IFN plus ribavirin therapy by HCV genotypes and IL28B genotype.

Miyagi Y, Nomura H, Yamashita N, Tanimoto H, Ito K, Masaki N, Mizokami M, Shibuya T.

J Infect Chemother. 2013 Feb;19(1):63-9. doi: 10.1007/s10156-012-0452-1. Epub 2012 Jul 21.

PMID:
22821355
[PubMed - indexed for MEDLINE]
6.

Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?

Pascale A, Serfaty L.

J Hepatol. 2013 Feb;58(2):391-4. doi: 10.1016/j.jhep.2012.09.023. Epub 2012 Oct 9.

PMID:
23063419
[PubMed - indexed for MEDLINE]
Free Article
7.

Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load.

Neukam K, Camacho A, Caruz A, Rallón N, Torres-Cornejo A, Rockstroh JK, Macías J, Rivero A, Benito JM, López-Cortés LF, Nattermann J, Gómez-Mateos J, Soriano V, Pineda JA.

J Hepatol. 2012 Apr;56(4):788-94. doi: 10.1016/j.jhep.2011.11.008. Epub 2011 Dec 13.

PMID:
22173157
[PubMed - indexed for MEDLINE]
8.

Interleukin-28B genotypes determine response to pegylated-interferon plus ribavirin therapy in patients with hepatitis C virus infection.

Osaki R, Nishimura T, Shioya M, Takeuchi T, Okumura Y, Nakahara T, Bamba S, Nakajo S, Fujiyama Y, Andoh A.

Mol Med Rep. 2012 Feb;5(2):525-8. doi: 10.3892/mmr.2011.655. Epub 2011 Nov 1.

PMID:
22052088
[PubMed - indexed for MEDLINE]
9.

Achievement of sustained viral response after switching treatment from pegylated interferon α-2b to α-2a and ribavirin in patients with recurrence of hepatitis C virus genotype 1 infection after liver transplantation: a case report.

Kawaoka T, Hiraga N, Takahashi S, Takaki S, Tsuge M, Nagaoki Y, Hashimoto Y, Katamura Y, Miki D, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Aikata H, Ochi H, Tashiro H, Ohdan H, Chayama K.

Intervirology. 2012;55(4):306-10. doi: 10.1159/000328661. Epub 2011 Aug 25.

PMID:
21865660
[PubMed - indexed for MEDLINE]
10.

Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.

Chen Y, Xu HX, Wang LJ, Liu XX, Mahato RI, Zhao YR.

Aliment Pharmacol Ther. 2012 Jul;36(2):91-103. doi: 10.1111/j.1365-2036.2012.05131.x. Epub 2012 May 16.

PMID:
22591106
[PubMed - indexed for MEDLINE]
11.

The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.

Zeuzem S, Buggisch P, Agarwal K, Marcellin P, Sereni D, Klinker H, Moreno C, Zarski JP, Horsmans Y, Mo H, Arterburn S, Knox S, Oldach D, McHutchison JG, Manns MP, Foster GR.

Hepatology. 2012 Mar;55(3):749-58. doi: 10.1002/hep.24744.

PMID:
22006408
[PubMed - indexed for MEDLINE]
12.

Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response.

Neukam K, Barreiro P, Rivero-Juárez A, Caruz A, Mira JA, Camacho A, Macías J, Rivero A, Soriano V, Pineda JA.

J Infect. 2013 Jul;67(1):59-64. doi: 10.1016/j.jinf.2013.03.010. Epub 2013 Mar 28.

PMID:
23542783
[PubMed - indexed for MEDLINE]
13.

Response to treatment in Brazilian patients with chronic hepatitis C is associated with a single-nucleotide polymorphism near the interleukin-28B gene.

Grandi T, da Silva CM, Amaral KM, Picon PD, Costi C, da Fré NN, Fiegenbaum M, Niel C, Rossetti ML.

Mem Inst Oswaldo Cruz. 2013 Feb;108(1):48-53.

PMID:
23440114
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype.

Rivero-Juarez A, Lopez-Cortes LF, Camacho A, Caruz A, Torres-Cornejo A, Martinez-Dueñas L, Ruiz-Valderas R, Torre-Cisneros J, Gutierrez-Valencia A, Rivero A.

AIDS. 2013 Jul 31;27(12):1941-7. doi: 10.1097/QAD.0b013e328360ea1e.

PMID:
23917425
[PubMed - indexed for MEDLINE]
15.

Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy.

Hsu CS, Hsu SJ, Chen HC, Tseng TC, Liu CH, Niu WF, Jeng J, Liu CJ, Lai MY, Chen PJ, Kao JH, Chen DS.

Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3719-24. doi: 10.1073/pnas.1100349108. Epub 2011 Feb 14.

PMID:
21321200
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Association of interleukin-28B and hepatitis C genotype 1 with a high viral load and response to pegylated interferon plus ribavirin therapy.

Takita M, Hagiwara S, Arizumi T, Hayaishi S, Ueda T, Kitai S, Yada N, Inoue T, Minami Y, Chung H, Ueshima K, Sakurai T, Kudo M.

Digestion. 2011;84 Suppl 1:56-61. doi: 10.1159/000333215. Epub 2011 Dec 2.

PMID:
22156487
[PubMed - indexed for MEDLINE]
17.

Natural cytotoxicity receptor-dependent natural killer cytolytic activity directed at hepatitis C Virus (HCV) is associated with liver inflammation, African American race, IL28B genotype, and response to pegylated interferon/ribavirin therapy in chronic HCV infection.

Meng Q, Rani MR, Sugalski JM, Judge CJ, Phat S, Rodriguez B, Blanton RE, Anthony DD.

J Infect Dis. 2014 May 15;209(10):1591-601. doi: 10.1093/infdis/jit677. Epub 2013 Dec 2.

PMID:
24302757
[PubMed - indexed for MEDLINE]
18.

Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis.

Jia Z, Ding Y, Tian S, Niu J, Jiang J.

PLoS One. 2012;7(9):e45698. doi: 10.1371/journal.pone.0045698. Epub 2012 Sep 21.

PMID:
23029188
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Pegylated interferon-α induced hypoferremia is associated with the immediate response to treatment in hepatitis C.

Ryan JD, Altamura S, Devitt E, Mullins S, Lawless MW, Muckenthaler MU, Crowe J.

Hepatology. 2012 Aug;56(2):492-500. doi: 10.1002/hep.25666. Epub 2012 Jun 11.

PMID:
22334511
[PubMed - indexed for MEDLINE]
20.

[Association between the influential factors and the effectiveness of pegylated interferon alpha-2a plus ribavirin as a combination treatment for chronic hepatitis C patients].

He LL, Chen Z, Chen Y, Xu H, Tang H, Lei BJ, Lei XZ.

Zhonghua Gan Zang Bing Za Zhi. 2011 Jan;19(1):34-7. doi: 10.3760/cma.j.issn.1007-3418.2011.01.010. Chinese.

PMID:
21272456
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk